Aim to evaluate the effect of Glucose-dependent insulinotropic polypeptide (GIP) with the infusion of rhIL-6 or placebo. Men with type 2 diabetes not treated with insulin [n=9, age 54.9± 9.7(mean ±SD) yr, body mass index 34.8±6.1 kg/m2] received intravenous infusion with either recombinant human rhIL-6 or placebo. There is no difference in the response of GIP secretion between both rhIL-6 or placebo infusion. In this paper, the problem is investigated considering hazard rate function of Gompertz-Makeham distribution.